PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.

Onco Targets Ther · 2014 · PMC4199823 · PMID 25336969

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantP =0.060so close (0.05 < p ≤ 0.1)

In patients with high PTK7 expression, the difference between cohort A and cohort C was borderline significant ( P =0.060; Figure 2C ), whereas a significant difference between cohorts B and C was observed (3-year DFS: 95.2% versus 20.8%; P =0.001; Figure 2D ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.